Subject: Corrigendum to the Notice of Extra-Ordinary General Meeting.
Ref.: Extra-Ordinary General Meeting ('EGM') scheduled to be held on Saturday, 5th March, 2022 at 4.00 p.m. (I.S.T.) through Video Conferencing/ Other Audio Video Means ('VC'/ 'OAVM') - Intimation sent on 11th February 2022
Dear Sir/ Madam,
This is in reference to the notice dated 8th February 2022 ("EGM Notice") convening the Extra Ordinary General Meeting of the shareholders ("EGM") of Morepen Laboratories Limited (the "Company") scheduled to be held on Saturday, 5th March 2022 at 4.00 p.m. (I.S.T.) through Video Conferencing/ Other Audio Video Means ('VC'/ 'OAVM') to transact the business as set out therein. The dispatch of said EGM Notice has completed by the Company on 11th February 2022.
Reference is invited to the page no. 19; point no. 'X' bearing heading 'Conversion Price and Relevant Date' of the Explanatory Statement of the said EGM Notice. The same be read with following amendments:
The paragraph 3 shall be replaced with the following paragraph:
"Further, pursuant to Clause 10 (c) of the Articles of Association of the Company, the price of Equity Shares, arising out of conversion of CCPS, has been arrived at Rs. 51.88/- (Rupees Fifty-One and Eighty-Eight Paise Only) each as on relevant date as per the valuation report of Corporate Professionals Valuation Services Private Limited having IBBI Registration Number IBBI/RV-E/02/2019/106, a registered valuer. The valuation report of the Registered Valuer shall be available on the website of the Company at https://morepen.com/public/uploads/investor/Morepen621a41cb75213.pdf"
A new paragraph 5 shall be added after the existing paragraph 4.
"The price calculated as per Regulation 164(1) of Chapter V of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, being higher than the price determined as per the valuation report, has been considered as the floor price for issuance of Equity Shares arising out of conversion of CCPS into Equity Shares."
Morepen Laboratories Limited
CIN NO. L24231 HP1984PLC006028
Corp. Off.: 2nd Floor, Tower C, DLF Cyber Park, Udyog Vihar-III,Sector-20, Gurugram, Haryana-122016, INDIA
All other contents of the EGM Notice remain unchanged.
This corrigendum shall form an integral part of the EGM Notice and shall also be available at Investor section of the Company's website www.morepen.com, on the website of
National Securities Depository Limited ('NSDL') www.evoting.nsdl.com and on the website of the Stock Exchanges i.e., National Stock Exchange of India Limited and BSE Limited at www.nseindia.com and www.bseindia.com, respectively.
An email is being sent to those members to whom EGM Notice was sent on 11th February 2022 and public notice is also being published in the newspapers.
You are requested to take the same on record.
Thanking you.
Yours faithfully,
For Morepen Laboratories Limited
Vipul Kumar Srivastava
Company Secretary
Morepen Laboratories Limited
CIN NO. L24231 HP1984PLC006028
Corp. Off.: 2nd Floor, Tower C, DLF Cyber Park, Udyog Vihar-III,Sector-20, Gurugram, Haryana-122016, INDIA
Morepen Laboratories Ltd. published this content on 26 February 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 26 February 2022 16:30:06 UTC.
Morepen Laboratories Limited is a pharmaceutical company. The Company is in the business of manufacturing, producing, developing and marketing a range of active pharmaceutical ingredients (APIs), branded and generic formulations and also home health products. Its APIs include Apixaban, Edoxaban, Linagliptin, Linagliptin + Metformin, Empagliflozin, Empagliflozin + Metformin, Atorvastatin, Rosuvastain, Rivaroxaban, Febuxostat, Montelukast (Oral), Montelukast (Chewable), among others. Its finished formulations include Intebact Capsules, Intelicaps Lax, Rythmix Kid Drop, Rythmix Kid Syrup, Kompact Powder, Saltum and Acifix 3X Suspension among others. Its home health products include Dr. Morepen 49W Room Air Purifier with HEPA Filter, Dr. Morepen VP06 Breathe Free Vaporizer, Dr. Morepen CN06 Compressor Nebulizer and Dr. Morepen ST03 Dual Head Stethoscope, among others. Its subsidiaries include Dr. Morepen Limited, Morepen Devices Limited, and Total Care Limited.
MOREPEN LABORATORIES LIMITED 